Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Lipid-Lowering Therapy with PCSK9 Inhibitors: Familial Hypercholesterolemia vs. General Population Outcomes
Anno:
2024
Background: Dyslipidemic patients, particularly those with familial hypercholesterolemia (FH), are at increased risk of cardiovascular events and require beginning a full treatment. This study aims to compare the long-term effects of PCSK9i treatment in FH and non-FH dyslipidemic patients. Methods: The study enrolled 381 dyslipidemic patients receiving PCSK9 inhibitors…
Leggi di più
Long-Term Follow-Up in Patients on PCSK9 Inhibitor Therapy: Combining Fast Track Strategy and Outpatient Management
Anno:
2024
BACKGROUND: Dyslipidemia is a significant risk factor for cardiovascular diseases, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as an effective treatment option. This study aims to investigate the lipid profile in the long-term follow-up of dyslipidemic patients receiving PCSK9 inhibitor therapy in an entirely outpatient setting….
Leggi di più
A Clash of Cholesterol Titans: Statin-Intolerant vs. Statin-Tolerant Patients on PCSK9 Inhibitors in long term follow-up
Anno:
2024
Introduction: Statin intolerance remains a clinical challenge in the management of dyslipidemia. This study aimed to investigate whether patients with statin intolerance, receiving PCSK9 inhibitors, exhibit lipid profile improvement different from those obtained in those without statin intolerance. Methods: In this monocentric outpatient study we enrolled 381 dyslipidemic patients…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram